-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users
Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users
Indivior PLC (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better understand how buprenorphine can reduce fentanyl-induced respiratory depression. The study entitled "Modelling buprenorphine reduction of fentanyl-induced respiratory depression" is available online and will appear in an upcoming print issue of JCI Insight, a peer-reviewed journal. The study was supported by Indivior.
This pharmacokinetic/pharmacodynamic study aimed at modeling the interaction of buprenorphine and fentanyl at the level of the mu-opioid receptor on minute ventilation under elevated carbon dioxide levels in opioid-naïve volunteers and chronic opioid users. Data used for modeling were from a clinical pharmacology study recently published in PLOS ONE. The main objective of the modeling was to characterize the effects of escalating intravenous fentanyl doses (0.25-0.70 mg/70 kg range in chronic opioid users) on respiratory depression compared to the intravenous infusion of either placebo or buprenorphine targeting plasma concentrations within the 0.2-5 ng/mL range.
Buprenorphine medications for opioid use disorder has been shown to reduce illicit opioid use and opioid-related mortality. This analysis describes another mechanism by which buprenorphine may reduce opioid overdose deaths. The modeling data indicate that buprenorphine plasma concentrations of 2 ng/mL and higher may have a protective effect against fentanyl-induced respiratory depression in chronic opioid users, with a reduced probability of apnea following exposure to high fentanyl doses.The model shows that when MOR occupancy by buprenorphine is sufficiently high, fentanyl is unable to activate the MOR and consequently will not cause additional respiratory depression on top of the mild respiratory effects of buprenorphine in that population.
"These modeling data show that buprenorphine plasma concentrations of 2 ng/mL and higher seem to have a protective effect against fentanyl-induced respiratory depression," stated Christian Heidbreder, PhD, chief scientific officer, Indivior. "Although the source study was conducted in a controlled setting and in a relatively small number of chronic opioid users, the ability of buprenorphine to reduce the risk of serious respiratory events triggered by fentanyl was demonstrated and warrants further investigation in a real-world setting."
Photo: Courtesy of Vladislav Muslakov on Unsplash
Related News
Indivior PLC (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better understand how buprenorphine can reduce fentanyl-induced respiratory depression. The study entitled "Modelling buprenorphine reduction of fentanyl-induced respiratory depression" is available online and will appear in an upcoming print issue of JCI Insight, a peer-reviewed journal. The study was supported by Indivior.
分割器PLC(OTCPK:INVVY)(LON:INV)已出版研究治疗阿片类药物使用障碍的丁丙诺啡和有效的合成阿片类药物芬太尼之间的竞争相互作用的模拟数据,以更好地理解丁丙诺啡如何减轻芬太尼诱导的呼吸抑制。这项题为“丁丙诺啡减少芬太尼引起的呼吸抑制的模型”的研究可在网上获得,并将发表在即将出版的同行评议期刊JCI Insight的印刷版上。这项研究得到了Indior的支持。
This pharmacokinetic/pharmacodynamic study aimed at modeling the interaction of buprenorphine and fentanyl at the level of the mu-opioid receptor on minute ventilation under elevated carbon dioxide levels in opioid-naïve volunteers and chronic opioid users. Data used for modeling were from a clinical pharmacology study recently published in PLOS ONE. The main objective of the modeling was to characterize the effects of escalating intravenous fentanyl doses (0.25-0.70 mg/70 kg range in chronic opioid users) on respiratory depression compared to the intravenous infusion of either placebo or buprenorphine targeting plasma concentrations within the 0.2-5 ng/mL range.
这项药代动力学/药效学研究旨在模拟在阿片类药物单纯志愿者和慢性阿片类药物使用者二氧化碳水平升高的情况下,丁丙诺啡和芬太尼在单位阿片受体水平上对分钟通气量的相互作用。用于建模的数据来自最近发表在《公共科学图书馆·综合》上的一项临床药理学研究。建模的主要目的是比较静脉注射芬太尼剂量增加(慢性阿片类药物使用者为0.25-0.70 mg/70公斤)与静脉滴注安慰剂或丁丙诺啡对呼吸抑制的影响,目标血浆浓度在0.2-5 ng/毫升范围内。
Buprenorphine medications for opioid use disorder has been shown to reduce illicit opioid use and opioid-related mortality. This analysis describes another mechanism by which buprenorphine may reduce opioid overdose deaths. The modeling data indicate that buprenorphine plasma concentrations of 2 ng/mL and higher may have a protective effect against fentanyl-induced respiratory depression in chronic opioid users, with a reduced probability of apnea following exposure to high fentanyl doses.The model shows that when MOR occupancy by buprenorphine is sufficiently high, fentanyl is unable to activate the MOR and consequently will not cause additional respiratory depression on top of the mild respiratory effects of buprenorphine in that population.
丁丙诺啡治疗阿片使用障碍的药物已被证明可以减少非法阿片使用和阿片相关死亡率。这项分析描述了丁丙诺啡可能减少阿片类药物过量死亡的另一种机制。模拟数据表明,丁丙诺啡血浆浓度在2 ng/mL或更高时,可能对慢性阿片使用者芬太尼引起的呼吸抑制具有保护作用暴露于高剂量芬太尼后,呼吸暂停的可能性降低。该模型显示,当丁丙诺啡的MOR占有率足够高时,芬太尼不能激活MOR,因此在该人群中,除了丁丙诺啡轻微的呼吸作用外,芬太尼不会造成额外的呼吸抑制。
"These modeling data show that buprenorphine plasma concentrations of 2 ng/mL and higher seem to have a protective effect against fentanyl-induced respiratory depression," stated Christian Heidbreder, PhD, chief scientific officer, Indivior. "Although the source study was conducted in a controlled setting and in a relatively small number of chronic opioid users, the ability of buprenorphine to reduce the risk of serious respiratory events triggered by fentanyl was demonstrated and warrants further investigation in a real-world setting."
“这些模拟数据表明,丁丙诺啡的血浆浓度在2 ng/ml或更高时,似乎对芬太尼诱导的呼吸抑制有保护作用,”声明说。克里斯蒂安·海德布雷德,博士,Indior首席科学官。虽然来源研究是在受控环境下进行的,而且是在相对较少的慢性阿片类药物使用者中进行的,但丁丙诺啡能够降低由芬太尼引发的严重呼吸事件的风险是被证明的,因此需要在现实世界中进行进一步的研究。
Photo: Courtesy of Vladislav Muslakov on Unsplash
图片:由弗拉迪斯拉夫·穆斯拉科夫在UnSplash上提供
Related News
相关新闻
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧